SGCG and glioblastoma: Considering that in about 50% GBM patients, type I and/or type II IFN family genes are deleted intrinsically [131], this suggests that Hypericin-PDT elicited immunogenicity will not be compromised and should be considered for its potential clinical application in GBM.